Introduction {#Sec1}
============

Since the 1980s, standard management of anal canal carcinoma (ACC) has been definitive chemoradiation therapy (CRT), with salvage abdominal-perineal resection (APR) for those who fail CRT \[[@CR1]-[@CR3]\]. Although CRT has been demonstrated in several randomized controlled trials as effective treatment for ACC, it is associated with significant toxicities \[[@CR4]-[@CR6]\]. Treatment breaks in up to 40-50% of patients have been reported due to hematological, dermatological and gastrointestinal toxicities \[[@CR7],[@CR8]\]. Efforts have been made to reduce toxicities through newer chemotherapy regimens and radiotherapy (RT) techniques \[[@CR9]-[@CR11]\]. Development of more conformal RT techniques has reduced normal tissue toxicity and the need for unintended treatment breaks \[[@CR11]\].

RTOG 0529 demonstrated significantly lower hematological, gastrointestinal and dermatological toxicities with intensity-modulated radiotherapy (IMRT) compared to conventional 2D-planning in ACC treatment \[[@CR12]\]. Helical tomotherapy (HT) delivery, a newer RT technique, has shown improved target conformality, dose homogeneity and normal-tissue sparing compared to IMRT in other tumor sites \[[@CR12],[@CR13]\].

In Alberta, use of IMRT vs HT is dependent on center availability and preference. To date, only one published study compares dosimetric parameters of IMRT vs HT in ACC, but there are no published data comparing toxicities \[[@CR14]\]. Our objectives were to compare dosimetry and toxicities between these modalities.

Materials and methods {#Sec2}
=====================

Patient population {#Sec3}
------------------

This retrospective study included ACC patients treated with definitive CRT between 2008--2010 at two provincial tertiary cancer centers (Tom Baker Cancer Center (TBCC) and Cross Cancer Institute (CCI)). Approval for this study was obtained from the University of Calgary Conjoint Health Research Ethics board.

Patients were included if they were ≥18 years of age, had a histologic diagnosis of ACC, no other active malignancies, and were treated with curative-intent CRT with a primary planning target volume (PTV~primary~) dose of 54--55.4 Gy. All patients were treated with IMRT or HT, and chemotherapy consisting of 2 cycles of 5-FU and 1--2 cycles of mitomycin C (MMC) or cisplatin. Patients who had metastatic disease, received PTV~primary~ dose \<54 or \>55.4 Gy, RT alone, and RT treatment techniques other than IMRT or HT were excluded.

Pre-treatment evaluation of all patients included tumor biopsy, clinical examination, baseline complete blood count (CBC), and computed tomography (CT) abdomen and pelvis. Tumor size was based on clinical exam (when documented) or imaging. Weekly CBC and toxicities (skin, gastrointestinal, genitourinary) while on treatment were graded using the RTOG acute scoring index \[[@CR15]\]. All blood counts were retrieved from the provincial clinical database (Alberta Netcare) during CRT and up to four weeks post last chemotherapy cycle. Hematological nadirs were recorded and analyzed.

Volume definitions {#Sec4}
------------------

Treatment plans were evaluated on an Eclipse workstation (Eclipse™ v8.9, Varian Medical Systems, Palo Alto, CA) without change to original planning target volumes delineated by treating physicians. Gross tumor volume (GTV), clinical target volume (CTV), planning target volume (PTV) were contoured, following the RTOG 0529 protocol, with deviations, if necessary, based on clinical judgment \[[@CR11]\]. CTV~primary~ included the primary tumor and involved lymph nodes \>1 cm identified on CT imaging and/or endoscopic ultrasound, plus a margin. CTV~nodes~ included regional lymph nodes at risk including peri-rectal, internal iliac, external iliac, obturator, presacral and inguinal lymph nodes. PTV~primary~ and PTV~node~ were generated with a uniform 1 cm margin around the CTV~primary~ and CTV~node~ respectively.

Organs at risk (OARs) included the bladder, peritoneal cavity, femoral heads, external genitalia (vulva in women, penis and scrotum in men), skin and bone marrow. These volumes were contoured on the existing plans. OAR volume definitions were based on the RTOG 0529 protocol except for small bowel and iliac crests \[[@CR11]\]. The peritoneal cavity included large and small bowel from the L4/5 junction to the level of the bladder dome, with exclusion of named structures. In lieu of iliac crests, bone marrow was delineated, consisting of the L5 vertebra, sacrum, and bilateral iliac crests. This was felt to better reflect bone marrow dose from SPECT bone marrow imaging and IMRT bone marrow sparing studies \[[@CR16],[@CR17]\]. Skin was generated as a 5 mm thick layer of tissue within the body contour, excluding PTV.

Plan evaluation {#Sec5}
---------------

The homogeneity of each plan with respect to PTV~primary~ and PTV~node~ was evaluated by the homogeneity (HI) and uniformity index (UI). HI was defined as the difference between D~max~ and D~min~ divided by the prescription dose, while UI was D~5~/D~95~. A value approaching 0 for HI and unity for UI indicates optimal dose homogeneity \[[@CR18],[@CR19]\]. For OARs, median and mean dose were reported. In addition, V30, V40, and V50 were recorded for the femoral heads, bladder and peritoneal cavity. For external genitalia, V20, V30, and V40 were recorded while V10 and V20 were recorded for bone marrow.

Statistical analysis {#Sec6}
--------------------

Patients were classified into two treatment cohorts: IMRT vs HT. A dosimetric comparison of plan homogeneity and OARs was performed. Disease-free survival (DFS), overall survival (OS), colostomy-free survival (CFS) and acute hematological and non-hematological toxicities were analyzed.

DFS was the interval between diagnosis and evidence of local, regional or metastatic failure, second primary, death or last follow-up for patients who did not fail. Local failure was evidence of persistent local disease or local recurrence. Regional failure was persistence, appearance or recurrence of regional nodal disease. Patients with persistent disease were considered as failing on the day of their first follow-up post CRT or date of biopsy-proven persistent disease (when available). Failure for OS was death due to any cause and was measured from diagnosis to the date of death or last follow-up. CFS was the interval between diagnosis and date of colostomy, including diverting colostomy and colostomy from salvage APR, or last follow-up for those not requiring a colostomy.

Results were analyzed with STATA Version 12.0 for Microsoft Windows (StataCorp LP, College Station, Texas). Chi-squared or Fisher exact testing was used to test differences between discontinuous variables. Wilcoxon rank-sum testing was used to test differences between continuous variables. DFS, OS, and CFS were analyzed using Kaplan-Meier survival analyses with log rank testing. *P* values of \<0.05 were considered statistically significant.

Results {#Sec7}
=======

Demographics {#Sec8}
------------

72 patients were diagnosed with ACC in Alberta between 2008--2010. Thirty-seven patients were excluded from the analysis (13 treated with a technique other than IMRT or HT, 7 received RT alone, 1 was treated with surgery alone, 1 had metastatic disease at diagnosis, 13 received a dose PTV~primary~ \<54 Gy or \>55.4 Gy, and 2 with missing data). Of the remaining 35 patients, 18 patients were treated with IMRT (all treated at TBCC) and 17 with HT (all treated at CCI). Patients treated with HT were treated on TomoTherapy® Hi-Art® system, version 2.2.4.1 (Accuray, Inc, Sunnyvale, CA). Patients treated with IMRT were treated on, Clinac 21EX, Clinac IX, or Triology (Varian Medical, Palo Alto, CA). Patient, tumor and treatment characteristics are summarized in Table [1](#Tab1){ref-type="table"}.Table 1**Baseline characteristics of ACC patients treated with chemoradiation by treatment cohortCharacteristicIMRT (N = 18) n (%)HT (N = 17) n (%)P-value\***Treatment center (TBCC/CCI)18 (100%)/0 (0%)0 (0%)/17 (100%)\<0.001Age, y (median(range))61 (45.1, 85.1)52 (34.8, 69.7)0.0045Gender, (male/female)6 (33.3%)/12 (66.7%)4 (23.5%)/13 (76.5%)0.71Smoker4 (22.2%)11 (64.7%)0.02ECOG statusECOG 04 (22.2%)7 (41.2%)0.29ECOG ≥114 (77.8%)10 (58.8%)HistologySquamous17 (94.4%)17 (100%)1.00Other1 (5.6%)0 (0%)AJCC T-stage11 (5.6%)0 (0%)1.0028 (44.4%)7 (41.2%)37 (38.9%)8 (47.1%)42 (11.1%)2 (11.8%)AJCC N-stageN014 (77.8%)11 (64.7%)1.00N1-34 (23.2%)6 (36.3%)Pretreatment Blood Counts(median(range))Hb (g/dL)124.5 (101, 156)141 (101, 163)0.10WBC (x10^9^/L)7.8 (5.1, 14.3)8.6 (5.2, 15.5)0.70Neutrophil (x10^9^/L)5.7 (2.8, 10.3)6.3 (2.7, 11.3)0.60Platelet (x10^9^/L)287.5 (146, 525)287 (167, 368)0.96RT dose to Primary Tumor, Gy54 (54, 55.4)54 (54, 54)0.04(median(range))ChemotherapyCisplatin + 5FU2 (11.1%)0 (0%)\<0.001MMC 1 cycle + 5FU16 (88.9%)1 (5.9%)MMC 2 cycles + 5FU0 (0%)16 (94.1%)\*Fisher exact testing used where any cell n \< 5, otherwise Chi-square testing used.

Both groups were balanced in regards to performance status, histology, T stage, N stage, and pre-treatment hematological parameters. The IMRT group had slightly older patients (p = 0.0045) and fewer smokers (p = 0.02). The median RT dose was the same between the groups, but dose was more variable in the IMRT group. Chemotherapy regimen was significantly different, with 16 patients in the IMRT group receiving 1 MMC cycle with 5-FU and 16 patients in the HT group receiving 2 MMC cycles with 5-FU (p \< 0.001).

Dosimetric outcomes {#Sec9}
-------------------

Figure [1](#Fig1){ref-type="fig"} shows a typical dose distribution on axial imaging at the level of PTV~primary~ for IMRT and HT techniques. Table [2](#Tab2){ref-type="table"} details the dosimetric coverage of treatment volumes and OARs by cohort. The HT group achieved more homogenous PTV~primary~ coverage compared to IMRT (HI p = 0.015, UI p \< 0.001). PTV~nodes~ coverage did not differ between the techniques, although HI approached significance (p = 0.06). IMRT achieved better bladder, peritoneal space and femoral head sparing (V30 and V40, p ≤ 0.01). Median and mean skin dose was also lower with IMRT (p \< 0.001). HT delivered lower dose to bone marrow (V10, p \< 0.01) and external genitalia (V20 and V30, p \< 0.001). A dosimetry model was constructed containing the factors of HI and UI for PTV~primary~ and HI for PTV~nodes~. No factor was significant for either outcome on multivariate analysis.Figure 1Dose distribution for ACC treated with IMRT vs HT.Table 2**Dosimetric coverage of treatment volumes and OARs by treatment cohortParameterIMRTHTP-value\*Median (range), MeanMedian (range), Mean**PTV~primary~HI0.28 (0.10, 1.09), 0.510.14 (0.05, 0.36), 0.180.015UI1.06 (1.04, 1.52), 1.091.03 (1.01, 1.07), 1.03\<0.001PTV~node~HI0.42 (0.14, 1.25), 0.480.55 (0.33, 0.79), 0.540.06UI1.12 (1.04, 1.52), 1.161.17 (1.09, 1.21), 1.160.15BladderV3094 (51, 100), 88.8100 (94, 100), 990.009V4056.5 (13, 92), 55.596 (44, 100), 90.9\<0.001V5014 (0.9, 54), 17.528 (0.2, 35), 210.37Mean (Gy)40.9 (32.4, 49.5), 41.347 (38.3, 49.2), 46.50.002Median (Gy)41.6 (30.3, 51.1), 41.547.1 (37.1, 49.0), 46.50.002Bone MarrowV1082.5 (47, 98), 78.667 (63, 75), 67.40.007V2062.5 (22, 88), 60.956 (51, 60), 560.08Mean (Gy)27.6 (12.4, 37.4), 27.226.2 (23.1, 28.5), 26.30.39Median (Gy)29.4 (9.1, 44.3), 28.928.3 (21.1, 33.4), 28.30.81Femoral headsV3068.5 (15, 99), 63.791 (76, 100), 90.3\<0.001V4014.5 (0, 50), 15.347 (27, 67), 50\<0.001V500 (0, 14), 1.20 (0, 26), 3.10.94Mean (Gy)32 (23.5, 41.9), 31.538.9 (35.4, 44.1), 39.1\<0.001Median (Gy)32.7 (23.6, 40.2), 31.639.3 (35.2, 43.2), 39.8\<0.001Peritoneal CavityV3026.5 (0.1, 66), 30.746 (6, 76), 44.60.01V4011 (0.9, 53), 17.234 (2, 66), 32.50.003V454.5 (0, 44), 9.222 (0.5, 57), 23.40.002V500.9 (0, 17), 1.72 (0, 27), 4.10.01Mean (Gy)20.2 (4.7, 36.4), 20.426.3 (9, 40.6), 25.60.04Median (Gy)19.7 (2.3, 41.8), 19.326 (4.1, 45.7), 25.40.09External GenitaliaV2098.5 (62, 100), 9173 (48, 98), 73.7\<0.001V3064 (19, 99), 6525 (6, 58), 27.1\<0.001V4027 (0, 86), 25.75 (0, 48), 9.80.02V502 (0, 44), 7.20.9 (0, 39), 4.40.11Mean (Gy)33.6 (21.8, 47.6), 33.625.1 (18, 38.9), 26\<0.001Median (Gy)33.3 (23.9, 48.9), 33.623.4 (18.9, 35.2), 24\<0.001SkinMean (Gy)17 (1.4, 21.3), 1623.1 (11.2, 26.8), 22\<0.001Median (Gy)15.9 (11.9, 19.2), 15.920.4 (6, 23.4), 19.1\<0.001\*Mann--Whitney test reported.

Toxicities {#Sec10}
----------

Acute hematological and non-hematological toxicities are presented in Table [3](#Tab3){ref-type="table"}. The most common toxicities were leukopenia and skin reaction. Grade 2+ hematological and non-hematological toxicities were similar between the groups. There were no significant differences in lower or upper gastrointestinal, genitourinary and skin toxicities. Additionally, febrile neutropenia and unscheduled treatment breaks did not differ between the two groups.Table 3**Grade 2+ toxicities in ACC patients treated with chemoradiation by treatment cohortToxicityTotalIMRTHTP-value\*(N = 35)(N = 18)(N = 17)n (%)n (%)n (%)**Grade 2+ Hematologic Toxicities^†^Leukopenia27 (77.1)13 (72.2)14 (82.4)0.69Neutropenia22 (62.9)10 (55.6)12 (70.6)0.36Thrombocytopenia13 (37.1)6 (33.3)7 (41.2)0.63Anemia11 (31.4)5 (27.8)6 (35.3)0.63Febrile neutropenia requiring hospitalization5 (14.3)1 (5.6)4 (23.5)0.18Grade 2+ Non-Hematologic Toxicities^†^Skin29 (82.9)14 (77.8)15 (88.2)0.66Upper GI9 (25.7)6 (33.3)3 (17.7)0.44Lower GI18 (51.4)12 (66.7)6 (35.3)0.06GU3 (8.6)2 (11.1)1 (5.9)1.00Unscheduled treatment break8 (22.9)6 (33.3)2 (11.8)0.23\*Fisher exact testing used where any cell n \< 5, otherwise Chi-square testing used.^†^RTOG acute radiation morbidity scoring criteria \[[@CR17]\].

Overall survival, disease-free survival and colostomy-free survival {#Sec11}
-------------------------------------------------------------------

Median follow-up for survivors at the time of analysis was 23.7 months. Estimated 3-year OS (IMRT 87.1% vs HT 100%, p = 0.13, Figure [2](#Fig2){ref-type="fig"}A) and DFS (IMRT 32.9% vs HT 51.8%, p = 0.68, Figure [2](#Fig2){ref-type="fig"}B) by Kaplan Meier analysis were similar between the two groups. Estimated 3-year CFS was also similar (IMRT 57.3% vs HT 70.2%, p = 0.29, Figure [2](#Fig2){ref-type="fig"}C).Figure 2Survival analysis of ACC patients treated with chemoradiotherapy by treatment cohort. **A**. Overall Survival. **B**. Disease-Free Survival. **C**. Colostomy-Free Survival.

Multivariate analysis was not performed on OS, due to the small number of events. Multivariate analysis for DFS and CFS outcomes was limited to 3 factors per model, accounting for the number of events. For each outcome, a demographics model consisting of age, smoking status, and treatment group was constructed. No factor was significant for either outcome.

Discussion {#Sec12}
==========

Advances in CRT for ACC have focused on toxicity reduction by alterations in chemotherapy regimens and radiotherapy delivery \[[@CR9]-[@CR11]\]. Large retrospective studies have shown promising results with cisplatin-based regimens compared to standard MMC treatment \[[@CR20],[@CR21]\]. However, two recent phase III trials, RTOG 98--11 and ACTII, failed to demonstrate superiority of cisplatin to MMC for ACC treatment \[[@CR9],[@CR10]\]. As such, ACC treatment with MMC and 5-FU remains standard of care.

Development of more conformal RT techniques has resulted in reduced normal-tissue toxicity. RTOG 0529 established superiority of IMRT to conventional 2D-planning in ACC treatment, with significant reduction in grade 2+ hematological, and grade 3+ gastrointestinal and dermatological toxicities using IMRT \[[@CR11]\]. Newer RT techniques, such as HT, have shown improved target conformality, dose homogeneity and normal-tissue sparing compared to IMRT \[[@CR12],[@CR13]\]. To date, there is only one study by Joseph et al. comparing dosimetry between HT and IMRT in ACC treatment \[[@CR14]\]. Our current retrospective study serves as the first study comparing toxicities in ACC treatment between these two techniques.

Seventy-two patients were diagnosed with ACC between our study period, but less than half of the patients were included in the current analysis. The majority of exclusions were based on RT technique and PTV~primary~ dose outside of 54--55.4 Gy, in an effort to maintain consistency in dose and treatment volumes. Chemotherapy was significantly different, with the majority of IMRT patients receiving 1 MMC cycle, versus 2 cycles in the HT group. Historically, patients treated at the center where HT is available have been treated with 2 MMC cycles due to physician preference, versus 1 MMC cycle at the center where only IMRT is available.

Similar to the dosimetric study by Joseph et al., HT in our study achieved superior target conformality compared to IMRT for PTV~primary~ coverage \[[@CR14]\]. OAR dose constraints in our study reflect those in RTOG 0529, with the exception of peritoneal cavity and bone marrow \[[@CR11]\]. In both the current study and the previous study by Joseph et al., IMRT achieved better sparing of bilateral femoral heads, while HT delivered lower dose to external genitalia. However, in our study, IMRT also achieved lower bladder, peritoneal cavity and skin doses, while Joseph et al. reported improvement in sparing of bladder and peritoneal cavity with HT. In addition, our study demonstrated better bone marrow and external genitalia sparing with HT \[[@CR14]\].

Differences in dose distribution and sparing of OARs between the two studies may be secondary to differences in calculation algorithms and study design. Although we found a significant difference between skin dose for IMRT and HT, it is known that there are large uncertainties in calculated skin dose for both the Eclipse analytic anisotropic algorithm and HT dose calculation algorithms \[[@CR22],[@CR23]\]. Furthermore, the planning study by Joseph et al. generated HT and IMRT plans on the same patients, thereby minimizing anatomical variations between the two groups. There was also strict adherence to contouring and planning guidelines \[[@CR14]\]. Our study, on the other hand, is retrospective with a larger sample of patients, and reflects real practice in a more generalized population.

Despite significant differences in OAR doses and chemotherapy regimens, acute hematological and non-hematological toxicities were similar between the groups. Three-year OS, DFS and CFS Kaplan Meier estimates were also similar. A recent retrospective study by our group suggests reduction of grade 3+ hematological and skin toxicities with 1 MMC cycle versus 2 cycles in ACC treatment, without compromise to OS, CFS and DFS \[[@CR24]\]. Potential differences in acute toxicities secondary to different chemotherapy regimens may have been mitigated by radiotherapy technique. Further studies with more balanced groups in regards to chemotherapy may assist in confirming this hypothesis and our current results.

This study has inherent limitations of a retrospective study from a single health authority. Despite utilizing a standardized toxicity grading scale, potential subjectivity exists in retrospectively grading toxicities. In effort to obtain consistency, a single reviewer graded all toxicities.

Conclusions {#Sec13}
===========

In our analysis of IMRT vs HT in ACC, differences in dose homogeneity and normal-tissue sparing were observed, but there were no significant differences in toxicities. Further investigation to increase cohort patient numbers should be performed, to definitively determine the impact of these techniques on toxicities and outcomes.
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